Mr. Tomáš Büchler M.D., Ph.D.
Future Forces Forum Future Forces Exhibition 2018
Czech Society for Oncology
Limiting the Sequelae of Hazardous Environmental Exposure: a Case for Collaboration of Oncology and Military Medicine
POSTER: The use of chemical, biological and nuclear weapons is a potential risk of modern warfare. Their use in conflicts and, more frequently, industrial or military accidents involving radioactive or chemical substances can result in long-term physical and psychological damage in exposed persons. In addition, military duty even in the time of peace can result in substantial hazardous exposure (Richards, 2011). Current treatment of cancer exposes patients to significant levels of radiation and noxious chemical stimuli. There are multiple common pathways for health damage after exposure to nonconventional warfare and cancer therapies (Table 1). Indeed, exposure to atomic bombings of Japanese cities at the end of World War II has been used to model long-term consequences of therapeutic and diagnostic radiation (Hall and Brenner, 2008). The population of cancer survivors is growing rapidly in the developed countries. Oncologists have been working on strategies to reduce long-term harm resulting from cancer therapies and to identify individuals at highest risk of complications. Newer studies are trying to identify and validate molecular predictors of susceptibility to long-term complications of therapy. Protocols are being developed for the follow-up of cancer survivors. These protocols are also potentially applicable to health surveillance of soldiers or civilians exposed to environmental hazards or nonconventional warfare. In conclusion, despite the fact that oncology is not an immediately obvious partner of military medicine, common efforts could result in significant advances in the prevention and management of long-term toxicities associated with exposure to ionizing radiation and cytotoxic chemicals.
Authors: Tomas Buchler, Bohuslav Melichar, Jana Prausova
on behalf of the Czech Society for Oncology
Tomas Buchler, M.D., Ph.D. is the Head of the Oncology Department and Associate Professor of Oncology at the Charles University First Faculty of Medicine and the Thomayer Hospital in Prague. He graduated from the Medical Faculty of the Comenius University in Bratislava in 2000. After graduation, he worked at the Department of Haematooncology of the University Hospital in Brno. From 2004 to 2006 he worked as a researcher at Oxford University, and subsequently as a Medical Oncology Registrar at the University College Hospital and the St Bartholomew's Hospital in London. Since 2007 he has been working at the Thomayer Hospital in Prague. Dr Buchler is board-certified in Medical Oncology and Radiation Oncology and is a member of the European Society of Medical Oncology (ESMO). His interests include urogenital malignancies and colorectal cancer. He has published mainly on the targeted treatment of renal cancer and other malignancies and long-term complications of cancer treatment. Currently, he is serving as the Scientific Secretary of the Czech Society or Oncology.